This is not the most recent version of the article. View current version (7 OCT 2009)

Intervention Protocol

Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease

  1. Robert Caslake2,
  2. Angus Macleod3,
  3. Natalie Ives4,
  4. Rebecca Stowe4,
  5. Carl Counsell1,*

Editorial Group: Cochrane Movement Disorders Group

Published Online: 18 JUL 2007

DOI: 10.1002/14651858.CD006661


How to Cite

Caslake R, Macleod A, Ives N, Stowe R, Counsell C. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease (Protocol). Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD006661. DOI: 10.1002/14651858.CD006661.

Author Information

  1. 1

    University of Aberdeen, Department of Medicine & Therapeutics, Aberdeen, UK

  2. 2

    University of Aberdeen, Medecine & Therapeutics, Aberdeen, UK

  3. 3

    University of Aberdeen, Medicine and Therapeutics, Aberdeen, UK

  4. 4

    University of Birmingham, University of Birmingham Clinical Trials Unit, Birmingham, UK

*Carl Counsell, Department of Medicine & Therapeutics, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK. carl.counsell@abdn.ac.uk.

Publication History

  1. Publication Status: Unchanged
  2. Published Online: 18 JUL 2007

SEARCH

This is not the most recent version of the article. View current version (07 OCT 2009)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Rakhee Krishna, Manal Ali, Ahmed A. Moustafa, Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson’s disease, Frontiers in Aging Neuroscience, 2014, 6,

    CrossRef